Misconstruing Single-Arm Study Data Lands BMS In Trouble With US FDA

 
• By Sarah Karlin-Smith
  
doctor that appears to be "holding" lungs
The BMS lung cancer drug was the subject of the FDA's third OPDP letter of the year. • Source: Shutterstock
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from Marketing & Advertising

More from Compliance